JAK1 and chronic myelomonocytic leukemia: A preclinical study of CMML found that the pro-neoplastic JAK1/2 pathway can be induced by the granulocyte-macrophage-colony-stimulating factor (GM-CSF) in CMML primary samples and can be successfully targeted by JAK inhibitors, including ruxolitinib [65].